BOARD OF DIRECTORS
EUGEN STEINER, MD, PhD
Chairman of the Board
Dr. Steiner is an investor and a life-science veteran. For more than 30 years, he has led several life-science companies across various geographies and stages of development. He has been with the venture capital firm HealthCap since 1997, serving as Venture Partner. He earned his MD and PhD degrees from Karolinska Institutet.
CARL-JOHAN SPAK, PhD
Dr. Spak is Senior advisor at Flerie Invest. He was previously Vice President Strategic Investments and Projects at Recipharm. He has 35 years experience in pharmaceutical industry with positions as managing director and CEO in small startup companies as well as larger pharmaceutical companies. Dr. Spak has a PhD in dentistry and pharmacology.
ANNE BLOCH THOMSEN, MD, PhD
Dr. Bloch Thomsen is Medical Director and Chief Medical Officer at Pfizer, Denmark. She has more than 15 years experiences from the pharmaceutical industry, whereof 10 years at Novo Nordisk as VP Medical & Science. She has strong track record in obesity, diabetes and the related drug projects within Novo Nordisk (e.g. Victoza). Her MD and PhD were defended at University of Aarhus.
MILAN ZDRAVKOVIC, MD, PhD
Dr. Zdravkovic is Chief Medical Officer and Head of R&D at Swedish Orphan Biovitrum. He has more than 20 years life science experience including senior positions at Novo Nordisk. He has worked in a number of therapeutic areas including diabetes and obesity and was involved in the development of Liraglutide for both the diabetes and obesity indications. Dr. Zdravkovic defended his thesis at University of Aarhus.
ASSOC. PROF. ULF HOLMBÄCK, PhD
Dr. Holmbäck is co-founder of Empros Pharma and part of the operational Empros team.
IN ADDITION TO OUR BOARD MEMBERS AND INVESTORS, WE WORK IN CLOSE COLLABORATION WITH A GROWING NUMBER OF INDUSTRIAL AND PROFESSIONAL PARTNERS.
RECIPHARM – recipharm.com
CDMO specialists taking products from early development through to commercial manufacturing
AERA – aera-ip.com
Intellectual property experts based in Copenhagen
Hospital-based early phase clinical trials (phase 0/I-IIa) in patients and healthy volunteers